Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 10/20 | 0.61 |
| ▸ | DYRK1B | Q9Y463 | 9/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10322269 | 0.92 | DYRK1A (0.72) | DYRK1ADYRK1BALDH1A1 | |
| SCHEMBL10321978 | 0.89 | DYRK1A (0.61) | DYRK1ADYRK1BALDH1A1 | |
| SCHEMBL10322383 | 0.86 | DYRK1A (0.62) | DYRK1ADYRK1BMAPTKDM4EALDH1A1 | |
| SCHEMBL10323943 | 0.84 | DYRK1A (0.85) | DYRK1ADYRK1B | |
| SCHEMBL10321742 | 0.83 | DYRK1A (0.61) | DYRK1ADYRK1BMAPTPPARGKDM4E | |
| SCHEMBL10321397 | 0.81 | DYRK1A (0.66) | DYRK1ADYRK1B | |
| SCHEMBL10321975 | 0.81 | DYRK1A (0.67) | DYRK1ADYRK1B | |
| SCHEMBL10321830 | 0.81 | DYRK1A (0.59) | DYRK1ADYRK1B | |
| SCHEMBL10320633 | 0.80 | DYRK1A (0.72) | DYRK1ADYRK1BALDH1A1 | |
| SCHEMBL10319139 | 0.80 | DYRK1A (0.84) | DYRK1ADYRK1BMAPTPPARGKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012098066-A1 | 1,6- AND 1,8-NAPHTHYRIDINES USEFUL AS DYRK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012098066-A1 | 1,6- AND 1,8-NAPHTHYRIDINES USEFUL AS DYRK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| US-20120184562-A1 | 1,6- AND 1,8-NAPHTHYRIDINES | LUK KIN-CHUN (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184562-A1 | 1,6- AND 1,8-NAPHTHYRIDINES | LUK KIN-CHUN (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184562-A1 | 1,6- AND 1,8-NAPHTHYRIDINES | LUK KIN-CHUN (US) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184562-A1 | 1,6- AND 1,8-NAPHTHYRIDINES | PSEN1, BRCA1, PSEN2 | DYRK1A 1366/4885DYRK1B 2109/4885MAPT 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.